To Buy Female Cialis No Insurance Visit Our Pharmacy ↓

DARE to PLAY Sildenafil Cream
THE BIG “O” (OVERVIEW)
If you're tired of uncertain quality and unproven options, you're not alone.
HOW IT WORKS
HERE IS WHAT SHE SAYS...

DARE to PLAY Sildenafil Cream

The drug's controversial approval yesterday comes on the heels of two previous unsuccessful attempts, lingering questions about safety, and uncertainty about whether or not it really works. After three applications, ownership by two drug companies, and one successful lobbying campaign, the female sexual-dysfunction drug flibanserin was approved yesterday by the Food and Drug Administration. Flibanserin, which will be sold under the brand name Addyi, has been billed as a remedy for women with Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity” in either gender. It’s also been rejected twice, for concerns that lingered even after an FDA advisory committee voted 18-6 in June to recommend approval. The drug has an effectiveness rate of somewhere between 8 and 13 percent, and can cause side effects like fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception. When it comes to market in October, Addyi’s label will carry a warning that it can’t be taken with alcohol. (And in the alcohol-safety study submitted to the FDA, oddly, 23 of the 25 participants were men, meaning the effects of drinking while on the drug still aren’t fully understood for the women who will be taking it.) Even so, it’s been hailed by supporters as a step towards gender equality in a previously overlooked area. “The FDA has approved 26 drugs marketed for the treatment of male sexual dysfunctions, compared to zero [now one] to address the most common form of female sexual dysfunction,” reads the website for Even the Score, a coalition of non-profits and health-care companies—including Sprout Pharmaceuticals, which makes flibanserin—that formed in 2013 to lobby for the drug’s approval. None of those 26 drugs, though, has the same purpose as flibanserin. Viagra and its ilk enhance physical arousal; despite its nickname as the “pink Viagra,” flibanserin was developed to enhance desire.

There is no true over-the-counter "female Viagra" available in UK pharmacies.
Viagra (sildenafil) is licensed for men and is not approved for female sexual dysfunction.
Some online sources may illegally sell prescription-only medications without consultation.
Herbal libido supplements are available OTC but are not proven to be effective.
Lubricants and moisturizers are widely available OTC without a prescription.
Buying prescription medicine without a prescription is illegal and potentially dangerous.
Always obtain medications through a legitimate consultation with a qualified prescriber.

Viagra is taken before sex and increases blood flow to the genitals; flibanserin is supposed to be taken daily and aims further north, changing the balance of neurotransmitters in the brain.

Product	Dosage	Quantity + Bonus	Price
Viagra Oral Jelly	100mg	30 + 5 Sachets	115.76€ 110.25€
Viagra Professional	100mg	10 Pills	44.09€ 41.99€
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€
Viagra Professional	100mg	20 Pills	71.14€ 67.75€
Viagra Super Active	100mg	120 + 16 Pills	198.37€ 188.92€
Viagra Generic	200mg	90 + 6 Pills	170.79€ 162.66€
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€
Viagra Generic	200mg	60 + 4 Pills	125.19€ 119.23€
Viagra Soft Tabs	100mg	10 Pills	36.93€ 35.17€
Viagra Generic	150mg	90 + 6 Pills	147.18€ 140.17€
Viagra Super Active	100mg	90 + 10 Pills	165.61€ 157.72€
Viagra Generic	25mg	90 + 6 Pills	105.03€ 100.03€
Viagra Generic	100mg	30 + 4 Pills	60.91€ 58.01€

The comparisons to Viagra, and the bumpy road to approval, have raised complicated questions about the nature of female desire, sexism in drug research, and what ought to qualify as a disorder. The drug’s approval has also raised a simpler question: What changed, exactly, between those two rejections and last night? The most obvious answer is good viagra click and collect public relations. Even the Score, which launched in 2013, has framed the issue as one of “women’s sexual health equity.” The group notes on its site that the World Health Organization considers “[pursuit of] a satisfying, safe and pleasurable sexual life” to be a human right, and has successfully solicited letters of support to the FDA from the editor of The Journal of Sexual Medicine, the president of the National Organization for Women, and members of Congress. In an June editorial in the Journal of the American Medical Association, three members of the FDA’s June advisory committee wrote of Even the Score: “Although flibanserin is not the first product to be supported by a consumer advocacy group [that is] in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA’s regulation have been particularly noteworthy, as have the extent of advocacy efforts.” But there’s another answer, too: Between the two rejections and the approval, the benchmark for success has changed. A highlights-only timeline of the drug’s rocky history looks like this: Flibanserin was originally developed as an antidepressant.

THE BIG “O” (OVERVIEW)

At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. The drug's controversial approval yesterday comes on the heels of two previous unsuccessful attempts, lingering questions about safety, and uncertainty about whether or not it really works. After three applications, ownership by two drug companies, and one successful lobbying campaign, the female sexual-dysfunction drug flibanserin was approved yesterday by the Food and Drug Administration.

Key takeaways

Flibanserin, which will be sold under the brand name Addyi, has been billed as a remedy for women with Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity” in either gender. It’s also been rejected twice, for concerns that lingered even after an FDA advisory committee voted 18-6 in June to recommend approval. The drug has an effectiveness rate of somewhere between 8 and 13 percent, and can cause side effects like fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception. When it comes to market in October, Addyi’s label will carry a warning that it can’t be taken with alcohol. (And in the alcohol-safety study submitted to the FDA, oddly, 23 of the 25 participants were men, meaning the effects of drinking while on the drug still aren’t fully understood for the women who will be taking it.) Even so, it’s been hailed by supporters as a step towards gender equality in a previously overlooked area.

CUSTOM FORMULATED

“The FDA has approved 26 drugs marketed for the treatment of male sexual dysfunctions, compared to zero [now one] to address the most common form of female sexual dysfunction,” reads the website for Even the Score, a coalition of non-profits and health-care companies—including Sprout Pharmaceuticals, which makes flibanserin—that formed in 2013 to lobby for the drug’s approval. None of those 26 drugs, though, has the same purpose as flibanserin. Viagra and its ilk enhance physical arousal; despite its nickname as the “pink Viagra,” flibanserin was developed to enhance desire. Viagra is taken before sex and increases blood flow to the genitals; flibanserin is supposed to be taken daily and aims further north, changing the balance of neurotransmitters in the brain. The comparisons to Viagra, and the bumpy road to approval, have raised complicated questions about the nature of female desire, sexism in drug research, and what ought to qualify as a disorder. After initial trials found it to be ineffective, it was redirected as a remedy for low female desire. The pharmaceutical company Boehringer Ingelheim submitted the drug for approval in 2010, though the agency rejected the application, noting that it didn’t seem to work very well for its new purpose, either. Sprout acquired the drug in 2011 and saw another rejection in 2013; this time, the FDA asked for additional safety studies and called for an advisory committee to investigate whether the risks outweighed the modest benefits.

The topic is often sensationalized in media as a search for a "pink Viagra."
This can create unrealistic expectations about a simple pill solving complex issues.
Ethical debates concern medicalizing normal variations in female sexual desire.
The high cost of new drugs creates issues of accessibility and healthcare inequality.
Off-label use of testosterone is common but lacks long-term safety data for women.
The primary focus should be on treating the underlying cause, not just the symptom.
Patient education and managing expectations are a critical part of the process.

Boehringer Ingelheim’s first two trials, submitted as part of the application the FDA rejected in 2010, had asked participants to keep a daily digital diary, reporting both the number of “satisfying sexual events” and the highest level of sexual desire they experienced each day. These measures were the study’s primary endpoints, or the main questions a drug trial is designed to answer.

The first FDA-approved female libido drug was flibanserin, marketed as Addyi in the US and sometimes available in the UK.
Female Viagra aims to target conditions like low libido, which can be caused by hormonal or psychological issues.
The effectiveness of female Viagra varies between individuals; some report notable improvements.
Cost of female libido medications in the UK varies and may not be covered by NHS prescriptions.
Researchers continue to explore new treatments for female sexual dysfunction with promising results.
Natural alternatives include herbal supplements like ginseng or maca, but their efficacy is not well-proven.
Discussing sexual health openly with a healthcare professional is recommended before starting treatment.
Some women use off-label medications or supplements to boost libido, but safety isn't always assured.
Female Viagra is not suitable for everyone; medical history and other medications should be considered.

A healthy, balanced diet supports overall health, including hormonal balance.
Regular physical exercise improves blood circulation, mood, and body image.
Adequate sleep is crucial for regulating hormones that influence sexual desire.
Stress management techniques (yoga, meditation) can reduce a major libido killer.
Reducing alcohol consumption can improve sexual response and overall health.
Quitting smoking improves blood flow to sexual organs and overall vitality.
Open communication with a partner is fundamental for a healthy sexual relationship.

Also unlike with the digital diaries, this measure showed a difference between flibanserin and placebos. When Sprout took over the development of flibanserin from BI in 2011, it conducted one more efficacy study of its own, but reshuffled the criteria. The new trial kept the number of satisfying sexual experiences as one primary endpoint, but this time around, participants weren’t asked to record their daily levels of desire; instead, the study used the FSFI—which had previously shown favorable results—as its other main measure. Meanwhile, outside of the FDA, Sprout, and Even the Score, a third thing has changed: Hypoactive Sexual Desire Disorder (HSDD), the condition that flibanserin was developed to treat, is no longer listed by the American Psychiatric Association as its own disorder. At the time that Spout acquired flibanersin, the most recent edition of the DSM was the DSM-IV, which drew a distinction between problems with female desire and problems with arousal. HSDD was its own entry; separately, Female Sexual Arousal Disorder was defined as “persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication swelling response of sexual excitement.” But in the DSM-V, published in 2013, the two were combined into one condition, “Female Sexual Interest/Arousal Disorder.” “Research suggests that sexual response is not always a linear, uniform process,” the APA wrote in an explanation of the changes, “and that the distinction between certain phases (e.g., desire and arousal) may be artificial”— a change that complicates the already-complicated arguments for and against the little pink pill.

If you're tired of uncertain quality and unproven options, you're not alone.

On Broadly: What It Feels Like to Take the Newly Approved ‘Female Viagra’ Let’s get past this “female Viagra” bullshit before we go any further. It couldn’t be less like Viagra if it were trying to evade an email spam filter, and comparing them is doubly confusing because most people don’t actually know much about Viagra to begin with. When you take Viagra nothing actually happens; or at least nothing noticeable. Contrary to popular myth it doesn’t suddenly increase your sex drive or make you instantly horny. It’s not for increasing your libido.

IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:

What it does is make it easier to get and maintain an erection once you’re aroused, something that can be achieved pretty simply with a single dose. It’s basically just hydraulics—a penis is a big dangling sack of blood, swinging around like an uncooked black pudding, and Viagra helps keep that sack pumped up. Addyi—or flibanserin, to use its non-commercial name—is radically different. Such therapies, dubbed ‘female Viagra' by the media, may help treat female sexual arousal disorder (FSAD), claimed to affect up to 40% of women. In a series of experiment on rabbits, researchers from Pfizer showed that genital blood flow was increased by the experimental drug UK-414, 495, a neutral endopeptidase. Reductions in genital blood circulation viagra sildenafil price have been proposed as a cause of FSAD. Writing in the British Journal of Pharmacology the researchers concluded that neutral endopeptidases ‘may restore sexual arousal in women adversely affected by FSAD'. Lead researcher Chris Wayman commented: ‘While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD'. There’s a new wonder drug in town. Addyi has been hailed as the “female Viagra,” a wonder drug that could do for unsatisfied women what Viagra did for their horny middle-aged boyfriends. For several years, its makers have fought a long and controversial campaign to get FDA approval for the drug, and the FDA has rejected it on the grounds that it doesn’t do enough to justify accepting the side effects. Then a PR campaign was launched, the FDA was put under intense pressure by feminist activists accusing them of patronizing sexism, and the drug was finally approved. It goes on sale in October; but the trouble is, it probably shouldn’t.

HOW IT WORKS

The drug’s approval has also raised a simpler question: What changed, exactly, between those two rejections and last night? The most obvious answer is good viagra click and collect public relations. Even the Score, which launched in 2013, has framed the issue as one of “women’s sexual health equity.” The group notes on its site that the World Health Organization considers “[pursuit of] a satisfying, safe and pleasurable sexual life” to be a human right, and has successfully solicited letters of support to the FDA from the editor of The Journal of Sexual Medicine, the president of the National Organization for Women, and members of Congress. In an June editorial in the Journal of the American Medical Association, three members of the FDA’s June advisory committee wrote of Even the Score: “Although flibanserin is not the first product to be supported by a consumer advocacy group [that is] in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA’s regulation have been particularly noteworthy, as have the extent of advocacy efforts.” But there’s another answer, too: Between the two rejections and the approval, the benchmark for success has changed. A highlights-only timeline of the drug’s rocky history looks like this: Flibanserin was originally developed as an antidepressant.

Vyleesi (bremelanotide)

After initial trials found it to be ineffective, it was redirected as a remedy for low female desire. The pharmaceutical company Boehringer Ingelheim submitted the drug for approval in 2010, though the agency rejected the application, noting that it didn’t seem to work very well for its new purpose, either. Sprout acquired the drug in 2011 and saw another rejection in 2013; this time, the FDA asked for additional safety studies and called for an advisory committee to investigate whether the risks outweighed the modest benefits. Boehringer Ingelheim’s first two trials, submitted as part of the application the FDA rejected in 2010, had asked participants to keep a daily digital diary, reporting both the number of “satisfying sexual events” and the highest level of sexual desire they experienced each day. These measures were the study’s primary endpoints, or the main questions a drug trial is designed to answer.

Exploratory Phase 2b RESPOND Study, Completed in 2023

Of the two, only the number of satisfying sexual experiences slightly increased with the use of flibanserin; the pill failed to make any meaningful difference on self-reported levels of desire. Put another way, people were having more sex—more good sex, even—but flibanserin wasn’t doing what it was supposed to do: make people want sex more in the first place. But in a move that would later become key to flibanserin’s approval, the studies also had a secondary endpoint: how the women scored on the Female Sexual Function Index (FSFI), a tool that assigns respondents a sexual-function score based on their sexual activity over the month leading up to the survey. Unlike the digital diaries, the FSFI asked participants to recall desire from the past four weeks, rather than the past day. Also unlike with the digital diaries, this measure showed a difference between flibanserin and placebos. On Broadly: What It Feels Like to Take the Newly Approved ‘Female Viagra’ Let’s get past this “female Viagra” bullshit before we go any further. It couldn’t be less like Viagra if it were trying to evade an email spam filter, and comparing them is doubly confusing because most people don’t actually know much about Viagra to begin with. When you take Viagra nothing actually happens; or at least nothing noticeable.

Tip	Explanation	Source Reference
Consult a healthcare professional before use	To ensure safety and appropriateness	NHS guidelines
Purchase from licensed sources	To avoid counterfeit products	Medicines and Healthcare products Regulatory Agency (MHRA)
Know the possible side effects	Be aware of adverse reactions	UK MHRA drug safety updates
Avoid mixing with alcohol	To prevent interactions	UK health advice

Contrary to popular myth it doesn’t suddenly increase your sex drive or make you instantly horny.

HERE IS WHAT SHE SAYS...

When Sprout took over the development of flibanserin from BI in 2011, it conducted one more efficacy study of its own, but reshuffled the criteria. The new trial kept the number of satisfying sexual experiences as one primary endpoint, but this time around, participants weren’t asked to record their daily levels of desire; instead, the study used the FSFI—which had previously shown favorable results—as its other main measure. Meanwhile, outside of the FDA, Sprout, and Even the Score, a third thing has changed: Hypoactive Sexual Desire Disorder (HSDD), the condition that flibanserin was developed to treat, is no longer listed by the American Psychiatric Association as its own disorder. At the time that Spout acquired flibanersin, the most recent edition of the DSM was the DSM-IV, which drew a distinction between problems with female desire and problems with arousal. HSDD was its own entry; separately, Female Sexual Arousal Disorder was defined as “persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication swelling response of sexual excitement.” But in the DSM-V, published in 2013, the two were combined into one condition, “Female Sexual Interest/Arousal Disorder.” “Research suggests that sexual response is not always a linear, uniform process,” the APA wrote in an explanation of the changes, “and that the distinction between certain phases (e.g., desire and arousal) may be artificial”— a change that complicates the already-complicated arguments for and against the little pink pill.

Increased genital blood flow

Such therapies, dubbed ‘female Viagra' by the media, may help treat female sexual arousal disorder (FSAD), claimed to affect up to 40% of women. In a series of experiment on rabbits, researchers from Pfizer showed that genital blood flow was increased by the experimental drug UK-414, 495, a neutral endopeptidase. Reductions in genital blood circulation viagra sildenafil price have been proposed as a cause of FSAD. Writing in the British Journal of Pharmacology the researchers concluded that neutral endopeptidases ‘may restore sexual arousal in women adversely affected by FSAD'. Lead researcher Chris Wayman commented: ‘While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future, although Pfizer has no current plans to develop medicines for FSAD'.

Though you cannot place an order quite yet...

There’s a new wonder drug in town. Addyi has been hailed as the “female Viagra,” a wonder drug that could do for unsatisfied women what Viagra did for their horny middle-aged boyfriends. For several years, its makers have fought a long and controversial campaign to get FDA approval for the drug, and the FDA has rejected it on the grounds that it doesn’t do enough to justify accepting the side effects. Then a PR campaign was launched, the FDA was put under intense pressure by feminist activists accusing them of patronizing sexism, and the drug was finally approved. It goes on sale in October; but the trouble is, it probably shouldn’t. It’s not for increasing your libido. What it does is make it easier to get and maintain an erection once you’re aroused, something that can be achieved pretty simply with a single dose. It’s basically just hydraulics—a penis is a big dangling sack of blood, swinging around like an uncooked black pudding, and Viagra helps keep that sack pumped up. Addyi—or flibanserin, to use its non-commercial name—is radically different.